Roche Holding AG
ROG
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Roche Holding AG News & Analysis
personal-finance
The US dollar looks overvalued. Should individual investors care?
Some things are a lot more important to professional investors than everybody else.
stocks
3 cheap Wide Moat stocks in a divided industry
All but a couple of shares in this industry have sold off. Our analysts think these three high quality companies have fallen too far.
stocks
Obesity drug stocks: Where to invest now
Eli Lilly and Novo Nordisk have staged big rallies. Here’s how investors can approach this potentially huge opportunity.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,053.00 | 23.90 | -0.26% |
| CAC 40 | 7,964.77 | 109.46 | -1.36% |
| DAX 40 | 23,734.02 | 315.72 | -1.31% |
| Dow JONES (US) | 46,912.30 | 398.70 | -0.84% |
| FTSE 100 | 9,735.78 | 41.30 | -0.42% |
| HKSE | 26,309.35 | 176.55 | -0.67% |
| NASDAQ | 23,053.99 | 445.80 | -1.90% |
| Nikkei 225 | 49,783.49 | 1,100.19 | -2.16% |
| NZX 50 Index | 13,611.51 | 34.70 | 0.26% |
| S&P 500 | 6,720.32 | 75.97 | -1.12% |
| S&P/ASX 200 | 8,788.40 | 22.10 | -0.25% |
| SSE Composite Index | 4,009.13 | 1.37 | 0.03% |